Novartis's Sandoz licenses proposed multiple sclerosis biosimilar
Posted by
www.biotecnika.org
The medicine is in Phase III clinical development for the treatment of
relapsing-remitting multiple sclerosis (RRMS).
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/novartiss-sandoz-licenses-proposed-multiple-sclerosis-biosimilar/articleshow/70955973.cms
Subscribe to:
Post Comments (Atom)
Post a Comment